NOLabs AB Achieves Break-Through In Fight Against MRSA-Bacteria

Main Category: MRSA / Drug Resistance
Also Included In: Medical Devices / Diagnostics;  IT / Internet / E-mail
Article Date: 01 Dec 2007 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Healthcare Prof:3 stars

3 (1 votes)


NOLabs AB, the Swedish medtech company developing innovative nitric oxide-containing medical devices based on the NitroSense(R) Technology, reported that it has achieved another important milestone in the development of a new line of products for wounds infected by MRSA-bacteria. MRSA stands for Methicillin Resistant Staphylococcus aureus, a bacterium that is particularly troublesome in hospital-acquired infections due to its resistance to several traditional antibiotics.

In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs' technology has a promising ability to kill a wide range of pathogens, including MRSA.

According to the US Centers for Disease Control and Prevention 126,000 hospitalisations are related to MRSA and 19,000 deaths are associated with serious MRSA infections every year in U.S. hospitals. Patients at risk for infection with MRSA include those with severe disease, recent surgery or indwelling medical devices, such as urinary catheters.

Goran Beijer, CEO of NOLabs says: "The recent results show that we are on the right track towards products with an enormous potential globally. The anti-microbial effect of NO will be key in several products that will prevent and/or treat infection depending on dosing. We are now accelerating our development program and expect to have the first products on the market during 2008."

NOLabs' NitroSense(R) Technology assures controlled, local delivery of pure nitric oxide in a well-defined concentration range during a well-defined time period. The main areas are prevention of catheter related urinary tract infections, relief of neuropathic pain and wound care products with an anti-bacterial effect.

For more information please visit our home page: http://www.nolabs.com

NOLabs is a Swedish medtech company developing and marketing nitric oxide-containing medical devices for various medical applications. Nitric oxide is a natural substance, produced by the human body. Its physiological effects include the control of local blood supply and the protection against microbes. In particular, NOLabs focuses on prevention of infection and pain relief for patients suffering from diabetes-related complications such as chronic wounds and neuropathic pain. Another focus area is the prevention and treatment of catheter-associated urinary tract infections. NOLabs has developed the innovative, cost efficient and highly effective NitroSense(R) Technology with a significant potential to address serious health issues that impact the lives of over 100 million people.

NOLabs AB
http://www.nolabs.com

Article adapted by Medical News Today from original press release.
Visit our mrsa / drug resistance section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
NOLabs AB. "NOLabs AB Achieves Break-Through In Fight Against MRSA-Bacteria." Medical News Today. MediLexicon, Intl., 1 Dec. 2007. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/90376.php>

APA
NOLabs AB. (2007, December 1). "NOLabs AB Achieves Break-Through In Fight Against MRSA-Bacteria." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/90376.php.

Please note: If no author information is provided, the source is cited instead.


MRSA / Drug Resistance

Most Popular Articles



Follow Our MRSA News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our MRSA / Drug Resistance Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »